X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dr. Reddys with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs AUROBINDO PHARMA - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB AUROBINDO PHARMA DR. REDDYS LAB/
AUROBINDO PHARMA
 
P/E (TTM) x 41.2 14.8 278.9% View Chart
P/BV x 3.2 3.8 82.7% View Chart
Dividend Yield % 0.9 0.4 209.5%  

Financials

 DR. REDDYS LAB   AUROBINDO PHARMA
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-17
AUROBINDO PHARMA
Mar-17
DR. REDDYS LAB/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs3,397895 379.5%   
Low Rs2,560622 411.6%   
Sales per share (Unadj.) Rs856.5254.6 336.4%  
Earnings per share (Unadj.) Rs78.039.3 198.5%  
Cash flow per share (Unadj.) Rs139.946.6 300.4%  
Dividends per share (Unadj.) Rs20.002.50 800.0%  
Dividend yield (eoy) %0.70.3 203.7%  
Book value per share (Unadj.) Rs739.8160.0 462.5%  
Shares outstanding (eoy) m165.74585.88 28.3%   
Bonus/Rights/Conversions BBESOP-  
Price / Sales ratio x3.53.0 116.7%   
Avg P/E ratio x38.219.3 197.8%  
P/CF ratio (eoy) x21.316.3 130.7%  
Price / Book Value ratio x4.04.7 84.9%  
Dividend payout %25.76.4 403.1%   
Avg Mkt Cap Rs m493,632444,390 111.1%   
No. of employees `00022.714.0 162.2%   
Total wages/salary Rs m31,06817,678 175.7%   
Avg. sales/employee Rs Th6,259.010,667.8 58.7%   
Avg. wages/employee Rs Th1,369.81,264.3 108.3%   
Avg. net profit/employee Rs Th569.71,645.8 34.6%   
INCOME DATA
Net Sales Rs m141,961149,157 95.2%  
Other income Rs m1,7151,159 148.0%   
Total revenues Rs m143,676150,316 95.6%   
Gross profit Rs m24,72234,343 72.0%  
Depreciation Rs m10,2664,276 240.1%   
Interest Rs m634667 95.0%   
Profit before tax Rs m15,53730,558 50.8%   
Minority Interest Rs m050 0.0%   
Prior Period Items Rs m3490-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,9657,597 39.0%   
Profit after tax Rs m12,92123,012 56.1%  
Gross profit margin %17.423.0 75.6%  
Effective tax rate %19.124.9 76.8%   
Net profit margin %9.115.4 59.0%  
BALANCE SHEET DATA
Current assets Rs m96,83792,062 105.2%   
Current liabilities Rs m84,19966,223 127.1%   
Net working cap to sales %8.917.3 51.4%  
Current ratio x1.21.4 82.7%  
Inventory Days Days73106 69.2%  
Debtors Days Days9868 144.3%  
Net fixed assets Rs m102,55262,919 163.0%   
Share capital Rs m829586 141.5%   
"Free" reserves Rs m121,79293,133 130.8%   
Net worth Rs m122,62193,719 130.8%   
Long term debt Rs m5,4491,814 300.4%   
Total assets Rs m218,165162,494 134.3%  
Interest coverage x25.546.8 54.5%   
Debt to equity ratio x00 229.6%  
Sales to assets ratio x0.70.9 70.9%   
Return on assets %6.214.6 42.6%  
Return on equity %10.524.6 42.9%  
Return on capital %12.932.7 39.4%  
Exports to sales %54.60-   
Imports to sales %9.40-   
Exports (fob) Rs m77,520NA-   
Imports (cif) Rs m13,274NA-   
Fx inflow Rs m81,67075,838 107.7%   
Fx outflow Rs m26,35530,224 87.2%   
Net fx Rs m55,31545,613 121.3%   
CASH FLOW
From Operations Rs m21,44432,786 65.4%  
From Investments Rs m-18,404-17,870 103.0%  
From Financial Activity Rs m-3,692-19,153 19.3%  
Net Cashflow Rs m-1,144-4,239 27.0%  

Share Holding

Indian Promoters % 25.5 54.1 47.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.4 8.0 67.9%  
FIIs % 35.3 27.7 127.4%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 10.2 150.0%  
Shareholders   75,885 69,601 109.0%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   GSK PHARMA  ASTRAZENECA PHARMA  DISHMAN PHARMA  PIRAMAL ENTERPRISES  NATCO PHARMA  

Compare DR. REDDYS LAB With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day up 260 Points; Pharma Stocks Top Gainers(Closing)

After opening the day in red, share markets in India witnessed positive trading activity throughout the day and ended the day on a positive note.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 0.4%

May 30, 2018 | Updated on May 30, 2018

For the quarter ended March 2018, AUROBINDO PHARMA has posted a net profit of Rs 5 bn (down 0.4% YoY). Sales on the other hand came in at Rs 40 bn (up 11.2% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Jun 22, 2018 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 8-QTR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS